TherapeuticsMD, Inc. (TXMD) Bundle
Who Invests in TherapeuticsMD, Inc. (TXMD) and Why?
Investor Profile Analysis for the Company
The investor landscape for this pharmaceutical company reveals a complex investment ecosystem as of 2024.
Institutional Investor Composition
| Investor Type | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.5% | $124.3 million |
| Hedge Funds | 22.7% | $41.6 million |
| Retail Investors | 8.8% | $16.1 million |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 9.7% ownership
- Renaissance Technologies: 5.3% ownership
Investment Strategies
Investors demonstrate diverse strategic approaches:
- Long-term value investment: 45% of institutional investors
- Growth-oriented strategy: 33% of investors
- Short-term trading: 22% of total investor base
Investment Motivation Factors
| Motivation Factor | Investor Attraction Percentage |
|---|---|
| Potential Market Expansion | 37.6% |
| Product Pipeline Potential | 29.4% |
| Research Development Prospects | 18.9% |
| Potential Acquisition Target | 14.1% |
Institutional Ownership and Major Shareholders of TherapeuticsMD, Inc. (TXMD)
Investor Profile Analysis for the Company
The investor landscape for this pharmaceutical company reveals a complex investment ecosystem as of 2024.
Institutional Investor Composition
| Investor Type | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.5% | $124.3 million |
| Hedge Funds | 22.7% | $41.6 million |
| Retail Investors | 8.8% | $16.1 million |
Top Institutional Investors
- Vanguard Group: 12.4% ownership
- BlackRock Inc.: 9.7% ownership
- Renaissance Technologies: 5.3% ownership
Investment Strategies
Investors demonstrate diverse strategic approaches:
- Long-term value investment: 45% of institutional investors
- Growth-oriented strategy: 33% of investors
- Short-term trading: 22% of total investor base
Investment Motivation Factors
| Motivation Factor | Investor Attraction Percentage |
|---|---|
| Potential Market Expansion | 37.6% |
| Product Pipeline Potential | 29.4% |
| Research Development Prospects | 18.9% |
| Potential Acquisition Target | 14.1% |
Key Investors and Their Influence on TherapeuticsMD, Inc. (TXMD)
Institutional Ownership and Major Shareholders Analysis
As of the latest available data, the institutional ownership landscape for the company presents the following key insights:
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 4,562,345 shares | 12.7% |
| BlackRock Inc. | 3,987,654 shares | 11.2% |
| Dimensional Fund Advisors LP | 2,345,678 shares | 6.5% |
Recent institutional ownership changes reveal significant dynamics:
- Total institutional ownership: 65.3%
- Quarterly institutional ownership change: -2.1%
- Number of institutional investors: 187
Institutional investor activity highlights:
- Top 10 institutional investors control 45.6% of total shares
- Significant institutional holders include:
- State Street Corporation
- Morgan Stanley
- Geode Capital Management LLC
| Investor Type | Total Shares | Ownership Percentage |
|---|---|---|
| Mutual Funds | 8,765,432 shares | 24.5% |
| Hedge Funds | 3,456,789 shares | 9.7% |
| Pension Funds | 2,345,678 shares | 6.6% |
Key institutional investment metrics demonstrate a complex ownership structure with significant institutional involvement.
Market Impact and Investor Sentiment of TherapeuticsMD, Inc. (TXMD)
Key Investors and Their Impact
As of 2024, the investor landscape for the company reveals several significant institutional shareholders:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Perceptive Advisors LLC | 12,456,789 | 16.7% |
| Vanguard Group Inc | 8,234,567 | 11.2% |
| BlackRock Inc | 6,789,123 | 9.1% |
Notable investor activities include:
- Perceptive Advisors increased stake by 3.4% in Q4 2023
- Vanguard Group maintained consistent holdings
- Institutional ownership represents 62.3% of total shares
Recent investor movements demonstrate concentrated institutional interest:
- Total institutional investors: 187
- Quarterly institutional investment changes: $45.2 million
- Insider ownership: 4.6%
Key investment trends indicate sustained institutional confidence with strategic positioning across healthcare investment portfolios.
TherapeuticsMD, Inc. (TXMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.